ABioM SIG Webinar: Tissue Biofabrication
Recorded: December 11, 2017
Purpose of ABioM-SIG
The objective of this SIG is to bring academia and industrial leaders together to promote the development of advanced biomanufacturing, foster collaborations among investigators in the field, and create a new mode of educating and training the next generation leaders and workforce in advanced biomanufacturing.
For more information or help email Membership@bmes.org.
All BMES members are welcome to join the ABioM SIG.
The ABioM SIG is an emerging field in biomedical engineering. It focuses on studying theories and technologies of manufacturing bio-related products, including natural or synthetic biomaterials, cells and cell-based therapeutic products such as individualized tissues and organoids, devices with biomaterials and/or cells as components. Unlike conventional biomanufacturing, advanced biomanufacturing builds on the groundbreaking discoveries such as 3D additive manufacturing, genome editing, cell reprogramming and transdifferentiation, systems and synthetic biology, stem cell biology, computational modeling, micro and nanofabrication, material genomes, biomaterials, tissue engineering and regenerative medicine. For example, the combination of 3D bioprinting technologies with micro-bio-fabrication as well as stem cell engineering has the potential to enable the manufacturing of off-the-shelf multiscale tissue assemblies or organ constructs—compatible with specific patients. Moreover, the combination of genome editing and computational modeling may allow for the formation of synthetic cells that serve as biofactories to produce therapeutic molecules or cells at will. The emerging of this new field offers tremendous opportunities to spur research, education, and industry growth and innovation.
Topics Covered by the ABioM-SIG:
Molecular Biomanufacturing including systems & synthetic biology, genome editing & structural DNA and RNA nanotechnology, organism engineering, and DNA manufacturing.
Cellular Biomanufacturing including cellular biofactories; micro- and nanoscale molecular design for generating cell and tissue assemblies, manufacturing multiscale biomolecule and tissue constructs, self-assembly and polymers/biomaterials including control of stereochemistry/chirality, systems integration between biological systems and electromechanical assemblies, stem cell engineering, and cell reprogramming.
Tissue and Organ Biomanufacturing including 3D tissue and organ printing, cell and tissue-based personalized medicine, material genome, cell and tissue micro- and nano-patterning, microphysiological systems, stem cell and regenerative medicine, enabling engineering technologies for production of multicellular constructs, microphysiological systems, organ-on-chips, disease modeling and drug testing, multiscale computational modeling and simulations, biomanufacturing process integration and scale-up, automated biomanufacturing processes, new printable biomaterials and bioreactors, biomanufacturing process characterization and validation, and regulatory sciences in advanced biomanufacturing.
Training and Education in Advanced Biomanufacturing including developing new degree programs in advanced biomanufacturing, fostering partnerships through engineering, physical sciences, business, and biomedical sciences with industry for advanced professional training, building infrastructures for educating and training future generation of leaders in advanced biomanufacturing.
Planned Activities: A council will be formed to operate and manage the SIG, and bylaws will be established under the leadership of the council to provide a framework for the operation and management of the SIG. An annual meeting will be held under the leadership of the council. This meeting will serve as a showcase for advanced biomanufacturing; it will also function as a platform to bring investigators, students, and leaders in the field together to review the field, identify grand challenges; and network and foster collaboration among members. Gordon-like conferences in advanced biomanufacturing will be developed to train and nurture young members to be leaders in advanced biomanufacturing. Workshops and forums will be organized to have a more rapid turnover in order to discuss latest works and future challenges in advanced biomanufacturing. International conferences and summer schools in advanced biomanufacturing will also be organized to foster international collaborations in advanced biomanufacturing. Liaisons for industries will be established to catalyze partnership of academia and industries and to encourage technology innovation and entrepreneurship. Finally, several topic-driven committees will be established to develop handbooks, guidance, text books, and other education and training materials in advanced biomanufacturing.
Founding Members of the ABioM-SIG include:
- Athanassios Sambanis, Professor, School of Chemical & Biomolecular Engineering, Georgia Tech; Program Director, Biomedical Engineering Program, National Science Foundation (NSF)
- Cheng Dong, Professor and Department Head, Department of Biomedical Engineering, Penn State University
- David Kaplan, Professor and Department Chair, Department of Biomedical Engineering, Tufts University
- Gang Bao, Professor, Department of Biomedical Engineering, Georgia Institute of Technology and Emory University
- Gilda Barabino, President of Biomedical Engineering Society (BMES), Professor and Dean of Grove School of Engineering, The City College of New York
- Kaiming Ye, Professor and Department Chair, Department of Bioengineering, Watson School of Engineering and Applied Sciences, State University of New York (SUNY) at Binghamton
- Kam W. Leong, Professor, Department of Biomedical Engineering, Duke University
- Peter Dillon, Professor and Department Chair, Department of Surgery, Hershey Medical Center, Penn State University
ABioM SIG Council:
- Chair (Kaiming Ye, ending October 2019)
- Chair-elect (Glenn Gaudette, starting October 2019)
- Secretary (Roland Kaunas, ending October 2020)
- Treasurer (Lance Lian, ending October 2021)
- (Elizabeth Lipke, Todd McDevitt, ending October 2020)
- (Randolph Ashton, Jeannine Coburn, Cheng Dong (ending October 2021)